Antibiotice S.A. (BVB:ATB)
Romania · Delayed Price · Currency is RON 2.010
-0.030 (-1.47%)
At close: Jun 8, 2026
Antibiotice Income Statement
Financials in millions RON. Fiscal year is January - December.
Millions RON. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 634.96 | 658.06 | 686.13 | 614.16 | 497.5 | 376.76 |
Other Revenue | 4.02 | 1.98 | 2.57 | 1.12 | 7.5 | 2.07 |
| 638.98 | 660.04 | 688.7 | 615.29 | 505 | 378.83 | |
Revenue Growth (YoY) | -4.14% | -4.16% | 11.93% | 21.84% | 33.31% | 9.10% |
Cost of Revenue | 259.48 | 259.54 | 254.42 | 232.64 | 187.45 | 146.97 |
Gross Profit | 379.5 | 400.5 | 434.28 | 382.65 | 317.55 | 231.86 |
Selling, General & Admin | 202.6 | 204.62 | 198.64 | 161.69 | 130.53 | 125.92 |
Other Operating Expenses | 74.07 | 72.11 | 83.39 | 95.66 | 91.94 | 47.57 |
Operating Expenses | 331.18 | 329.73 | 327.09 | 285.23 | 244.73 | 197.61 |
Operating Income | 48.32 | 70.77 | 107.19 | 97.42 | 72.81 | 34.25 |
Interest Expense | -4.61 | -4.47 | -4.54 | -4.15 | -3.59 | -3.52 |
Interest & Investment Income | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Exchange Gain (Loss) | -6.52 | -6.42 | 0.26 | -0.95 | -0.8 | -0.22 |
Other Non Operating Income (Expenses) | 0.12 | 0.21 | 0.04 | 0.08 | -0.18 | -0.21 |
EBT Excluding Unusual Items | 37.31 | 60.09 | 102.95 | 92.42 | 68.25 | 30.3 |
Gain (Loss) on Sale of Assets | 0.06 | 0.05 | 0.16 | 0 | 0.1 | - |
Asset Writedown | - | - | - | -0.9 | -3.04 | - |
Pretax Income | 37.37 | 60.15 | 103.11 | 91.52 | 65.31 | 30.3 |
Income Tax Expense | 5.68 | 8.38 | 0.91 | 10.44 | 13.84 | 0.36 |
Net Income | 31.69 | 51.77 | 102.2 | 81.09 | 51.47 | 29.94 |
Net Income to Common | 31.69 | 51.77 | 102.2 | 81.09 | 51.47 | 29.94 |
Net Income Growth | -67.51% | -49.35% | 26.04% | 57.54% | 71.92% | 13.46% |
Shares Outstanding (Basic) | 671 | 671 | 671 | 671 | 671 | 671 |
Shares Outstanding (Diluted) | 671 | 671 | 671 | 671 | 671 | 671 |
EPS (Basic) | 0.05 | 0.08 | 0.15 | 0.12 | 0.08 | 0.04 |
EPS (Diluted) | 0.05 | 0.08 | 0.15 | 0.12 | 0.08 | 0.04 |
EPS Growth | -67.50% | -49.35% | 26.04% | 57.54% | 71.92% | 13.46% |
Free Cash Flow | -106.26 | -70.17 | -3.63 | 39.43 | 78.09 | 15.39 |
Free Cash Flow Per Share | -0.16 | -0.10 | -0.01 | 0.06 | 0.12 | 0.02 |
Dividend Per Share | 0.036 | 0.036 | 0.021 | 0.083 | 0.008 | 0.003 |
Dividend Growth | 74.05% | 74.05% | -75.21% | 946.74% | 147.72% | -3.27% |
Gross Margin | 59.39% | 60.68% | 63.06% | 62.19% | 62.88% | 61.20% |
Operating Margin | 7.56% | 10.72% | 15.56% | 15.83% | 14.42% | 9.04% |
Profit Margin | 4.96% | 7.84% | 14.84% | 13.18% | 10.19% | 7.90% |
Free Cash Flow Margin | -16.63% | -10.63% | -0.53% | 6.41% | 15.46% | 4.06% |
EBITDA | 104.03 | 124.98 | 152.24 | 125.35 | 95.38 | 58.68 |
EBITDA Margin | 16.28% | 18.93% | 22.11% | 20.37% | 18.89% | 15.49% |
D&A For EBITDA | 55.71 | 54.2 | 45.06 | 27.93 | 22.57 | 24.43 |
EBIT | 48.32 | 70.77 | 107.19 | 97.42 | 72.81 | 34.25 |
EBIT Margin | 7.56% | 10.72% | 15.56% | 15.83% | 14.42% | 9.04% |
Effective Tax Rate | 15.19% | 13.93% | 0.88% | 11.40% | 21.19% | 1.20% |
Advertising Expenses | - | 22.63 | 27.51 | - | - | 11.01 |